About Exscientia
Exscientia is a company based in Oxford (United Kingdom) founded in 2012 by Chris Gibson was acquired by Recursion in October 2024. Exscientia has raised $428.63 million across 10 funding rounds from investors including Recursion Pharmaceuticals, Evotec and BlackRock. The company has 392 employees as of December 31, 2023. Exscientia has completed 1 acquisition, including Allcyte. Exscientia operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Oxford, United Kingdom
- Employees 392 as on 31 Dec, 2023
- Founders Chris Gibson
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Exscientia Plc
- Date of Incorporation 29 Jun, 2021
- Jurisdiction OXFORD, OXFORDSHIRE, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$428.63 M (USD)
in 10 rounds
-
Latest Funding Round
$2.3 M (USD), Grant
Dec 05, 2023
-
Investors
Recursion Pharmaceuticals
& 16 more
-
Employee Count
392
as on Dec 31, 2023
- Investments & Acquisitions
-
Acquired by
Recursion
(Oct 10, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Exscientia
Unlock access to complete
Unlock access to complete
Leadership Team
32 people
Data Analysis and Operations Team
30 people
Software Development Team
21 people
Senior Team
12 people
Product Management Team
11 people
Board Team
8 people
Operations Team
7 people
Finance and Accounting
6 people
Unlock access to complete
Funding Insights of Exscientia
Exscientia has successfully raised a total of $428.63M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $2.3 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Exscientia
Exscientia has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Recursion Pharmaceuticals, Evotec and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and startups.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Multiple investment strategies are pursued by this hedge fund.
|
Locked | Locked | Locked |
Investor details for Exscientia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exscientia
Exscientia has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Allcyte.
Investment portfolio details for Exscientia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of drugs for the treatment of cancer patients
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Exscientia
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Exscientia
Detailed financials for Exscientia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exscientia Comparisons
Peer comparison for Exscientia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Exscientia
Exscientia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Exscientia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exscientia
Complete news archive for Exscientia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exscientia
Exscientia was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Exscientia is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Chris Gibson is the current CEO of Exscientia. They have also founded this company.
Exscientia is a funded company, having raised a total of $428.63M across 10 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Exscientia is 392.
Exscientia was founded in 2012 in Oxford, United Kingdom, and operates in the biotechnology sector. AI technologies are integrated to develop therapeutics, including the identification of drug candidates, molecule design, and preclinical experiments. Targeted therapies and personalized treatment strategies are emphasized. Research findings are published, and presentations are made in the field of precision medicine.
Exscientia's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Exscientia has made 1 acquisition, including Allcyte.
Exscientia has 17 investors. Key investors include Recursion Pharmaceuticals, Evotec, BlackRock, Marshall Wace, and Gates Foundation.